Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy

Journal of Nuclear Medicine

Volumn 47, Issue 1, 2006, Pages 6-13

  Van Den Bossche, Bieke ^a   Van Belle, Simon ^a   De Winter, Frederic ^b   Signore, Alberto ^c   Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b OLV HOSPITAL   (Belgium)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

99mTc depreotide; Breast cancer; Endocrine therapy; Therapy prediction

Indexed keywords

ANASTROZOLE; DEPREOTIDE TC 99M; FULVESTRANT; LETROZOLE; SOMATOSTATIN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOSTATIN; TECHNETIUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; IN VIVO STUDY; MOLECULAR IMAGING; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY; TREATMENT RESPONSE; BREAST TUMOR; CLINICAL TRIAL; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 33847106134     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Steroid receptors in breast cancer: an NIH Consensus Development Conference, Bethesda, Maryland, June 27-29,1979. Cancer. 1980;46:2759-2963.
2. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer. 1983;52:479-485.
3. Reubi JC, Torhorst J. The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer. 1989;64:1254-1260.
4. Bloom ND, Tobin EH, Schreibman B, et al. The role of progesterone receptors in the management of advanced breast cancer. Cancer. 1980;45:2992-2997.
5. Nardelli GB, Lamaina V, Siliotti F. Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report). Eur J Gynaecol Oncol. 1986;7:151-158.
6. Xu Y, Song J, Berelowitz M, et al. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology. 1996;137:5634-5640.
7. 99mTc-depreotide. Eur J Nucl Med Mol Imaging. 2004;31:1022-1030.
8. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab. 1995;80:2974-2979.
9. Schulz S, Helmholz T, Schmitt J, et al. True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat. 2002;72:221-226.
10. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846.
11. van Eijck CH, Krenning EP, Bootsma A, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet. 1994;343:640-643.
12. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450-482.
13. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84-91.
14. 99mTc-P829. Cancer Res. 1998;58:1850-1859.
15. Lister-James J, Pearson D, De Rosch M, et al. Tc-99m P829: characterization of a technetium-99-labeled somatostatin receptor-binding peptide. In: Nicolini M, Mazzi U, eds. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. Vol. 5. Padova, Italy: SGE Editoriali; 1999:473-478.
16. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med. 1996;37:1016-1022.
17. Johnston SR, Haynes BP, Sacks NP, et al. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat. 1993;28:241-250.
18. Arimidex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2001.
19. Femara [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2005.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
21. Robertson JF, Jaeger W, Syzmendera JJ, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers: European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer. 1999;35:47-53.
22. Robertson JF, Willsher PC, Cheung KL, et al. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer. 1997;33:1774-1779.
23. Robertson JF, Howell A, Buzdar A, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat. 1999;58:157-162.
24. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683-687.
25. 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. Cancer Biother Radiopharm. 2004;19:205-210.
26. Cheung KL, Willsher PC, Pinder SE, et al. Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat. 1997;45:219-224.
27. Elliott DE, Li J, Blum AM, et al. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol. 1999;29:2454-2463.
28. Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer. 1997;74:492-501.
29. Georgiannos SN, Renaut A, Goode AW, et al. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery. 2003;134:827-834.
30. Johnston SR, Lu B, Dowsett M, et al. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res. 1997;57:3723-3727.
31. Stoll BA. Rechallenging breast cancer with tamoxifen therapy. Clin Oncol. 1983;9:347-351.
32. Osborne CK, Wiebe VJ, McGuire WL, et al. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992;10:304-310.
33. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer. 1996;73:5-12.
34. Fuqua SA, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat. 1995;35:233-241.
35. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer. 2000;82:501-513.
36. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926-935.
37. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
38. Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr Rev. 1997;18:701-715.
39. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 1997;57:2606-2610.